Results 21 to 30 of about 9,532 (171)

Population pharmacokinetics of pomalidomide [PDF]

Journal of Clinical Pharmacology, 2015
AbstractA population pharmacokinetic (PPK) model of pomalidomide was developed and the influence of demographic and disease‐related covariates on PPK parameters was assessed based on data from 6 clinical trials of pomalidomide (dose range, 0.5–10 mg) in healthy participants (n = 96) and patients with multiple myeloma (MM; n = 144).
Maria Palmisano, Simon Zhou
exaly   +3 more sources

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial [PDF]

, 2021
Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma.
Katodritou, E., Karlin, L., Vural, F., Bila, J., Salwender, H., Doyen, C., Facon, T., Leleu, X., Ukropec, J., Carson, R., Benboubker, L., Goldschmidt, H., Belotti, A., Lahuerta, J.J., Unal, A., Hulin, C., Cavo, M., Engelhardt, M., Schecter, J.M., APOLLO Trial Investigators, Mateos, M.-V., Meuleman, N., Rosinol Dacsh, L., Martinez Chamorro, C., Qiu, Y., Vlummens, P., Roerdink, H.T.J., Sonneveld, P., Tuglular, T., Iversen, B., Ahmadi, T., Hayri Ozsan, G., Amin, H., Vermeulen, J., Hajek, R., Moreau, P., Dytfeld, D., Toftmann Hansen, C., Symeonidis, A., Einsele, H., Oriol Rocafiguera, A., Besemer, B., Dimopoulos, M.A., Terpos, E., De La Rubia Comos, J., Knop, S., Baldini, L., Grosicki, S., Foà, R., Minnema, M., Pour, L., Beksac, M., Kampfenkel, T., Oriol, A., Kyrtsonis, M.-C., Boccadoro, M., Orfanidis, I., Wu, K.L., Offidani, M., Besisik, S., Alegre Amor, A., Zweegman, S., Mateos Manteca, M.-V., Delimpasi, S., Pehlivan, M.   +64 more
core   +6 more sources

In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma. [PDF]

Chirality
Pomalidomide is a 2nd‐generation chiral immunomodulatory (IMiDs) drugs and have antiangiogenic activity. Despite being teratogenic, it has been shown to be effective in treating multiple myeloma.
Vardhan G, Kumar V, Kumar A, Handu S, Dhamija P.   +4 more
europepmc   +2 more sources

Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients

Frontiers in Pharmacology, 2022
Objective: To explore the effect of pomalidomide on the maturation of monocyte-derived dendritic cells (moDCs) from healthy donors (HDs) and multiple myeloma (MM) patients.Methods: MoDCs were generated by the incubation of monocytes from peripheral blood
Xi Wang, Jingying Dai, Jingyi Xia, Zichen Ye, Xiaobing Huang, Wanjun Cao, Rong Xiao, Lin He   +7 more
doaj   +1 more source

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma

Therapeutic Advances in Hematology, 2022
Pomalidomide is a potent immunomodulatory agent that is currently a standard of care backbone for the treatment of multiple myeloma (MM) patients in the relapsed/refractory setting after exposure to lenalidomide and a proteasome inhibitor.
Despina Fotiou, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos   +3 more
doaj   +1 more source

Analytical Method Development and Validation for the Test Related Substances of Pomalidomide in Pomalidomide Capsules

, 2023
<p>The percent impurities of pomalidomide in capsules of 1mg, 2mg, 3mg, and 4mg were determined using an HPLC technique. The current study provides the pomalidomide method validation for related chemicals test's procedural design and acceptance ...
Dr. A. R. Chabukswar, Nilesh Kamble
core   +1 more source

Pomalidomide combinations are a safe and effective option after daratumumab failure [PDF]

, 2023
Purpose: Outcomes of multiple myeloma (MM) patients who are refractory to daratumumab are dismal and no standard of treatment exists for this patients’ population.
Heidel, Florian, Stauch, Thomas, Brioli, Annamaria, Zamagni, Elena, Gengenbach, Laura Sophie, Mancuso, Katia, Hilgendorf, Inken, Hochhaus, Andreas, Lilienfeld-Toal, Marie, Ernst, Thomas, Binder, Mascha, Engelhardt, Monika   +11 more
core   +1 more source

Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide

, 2021
Pomalidomide is an immunomodulatory drug used for relapsed and refractory multiple myeloma (RRMM). Hypothyroidism is an uncommon side effect of pomalidomide.
Qureshi, Anum, Rhee, Ji Hyun
core   +1 more source

Evidence For Pomalidomide In 2nd Line Treatment Of Relapse Refractory Multiple Myeloma

, 2021
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States (US). MM is an uncurable disease and current treatments are meant to delay progression and extend patient’s lives.
Thomas, PharmD, Ryan
core   +1 more source

Pomalidomide for Treatment of Relapsed and Refractory Multiple Myeloma

Клиническая онкогематология, 2015
Pomalidomide is a third-generation immunomodulatory drug recommended for patients with multiple myeloma refractory to lenalidomide and bortezomib. The safety profile is optimized for application in patients with intensive and continuous anti-tumor ...
Sergei Vyacheslavovich Semochkin
doaj   +1 more source